Inflammatory arthritis in patients with myelodysplastic syndromes: A multicenter retrospective study and literature review of 68 cases

Medicine (United States)

Volumn 93, Issue 1, 2014, Pages 1-10

  Mekinian, Arsène ^a   Braun, Thorsten ^a   Decaux, Olivier ^b   Falgarone, Géraldine ^c   Toussirot, Eric ^d   Raffray, Loic ^e   Omouri, Mohamed ^f   Gombert, Bruno ^g   De Wazieres, Benoit ^h   Buchdaul, Anne Laure ⁱ   Ziza, Jean Marc ^f   Launay, David ^j   Denis, Guillaume ^k   Madaule, Serge ^l   Rose, Christian ^m   Grignano, Eric ^a   Fenaux, Pierre ^a   Fain, Olivier ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c Hôpital Avicenne   (France)

^d UNIVERSITY HOSPITAL OF BESANÇON   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f Service de Rhumatologie   (France)

^g Hôpital de la Rochelle   (France)

^h NÎMES UNIVERSITY HOSPITAL   (France)

ⁱ CH Douai   (France)

^j LILLE UNIVERSITY HOSPITAL   (France)

^k Service de Cardiologie   (France)

^l Service d'Orthopédie et de Traumatologie CHG Albi   (France)

^m UNIV LILLE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; ETANERCEPT; HYDROXYCHLOROQUINE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADD ON THERAPY; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BONE EROSION; BRAIN HEMORRHAGE; CARDIOPULMONARY INSUFFICIENCY; CAUSE OF DEATH; CORTICOSTEROID THERAPY; DAS28; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; INFECTION; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MYELODYSPLASTIC SYNDROME; POLYARTHRITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; VERY ELDERLY;

EID: 84892967412     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000011     Document Type: Article

References (47)

1. Aggarwal S, van de Loosdrecht AA, Alhan C, Ossenkoppele GJ, Westers TM, Bontkes HJ. Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy. Br J Haematol. 2011;153:568-581.
2. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsk J, Wolfe F, Hawker G. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569-2581.
3. Al Ustwani O, Francis J, Wallace PK, Ambrus J Jr, Wetzler M. Treating myelodysplastic syndrome improves an accompanying autoimmune disease along with a reduction in regulatory T-cells. Leuk Res. 2011;35:e35-36.
4. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324.
5. Baron F, Suciu S, Amadori S, Muus P, Zwierzina H, Denzlinger C, Delforge M, Thyss A, Selleslag D, Indrak K, Ossenkoppele G, de Witte T. Value of infliximab (Remicade) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group. Haematologica. 2012;97:529-533.
6. Berthelot JM, Hamidou M, Dauty M, Rodet D, Maugars Y, Prost A. Joint manifestations in myelodysplastic syndromes. A report of three cases presenting as polymyalgia rheumatica. Rev Rhum Engl Ed. 1997;64:95-100.
7. Berthier S, Magy N, Gil H, Schneider MB, Vuitton DA, Dupond JL. EMyelodysplasias and systemic diseases. A non-fortuitous association. Rev Med Interne. 2001;22:428-432.
8. Beyne-Rauzy O, Revel V, Desfossez V, Bousquet E, Nourhashemi F, Adoue D. ERS3PE syndrome: an acute edematous polyarthritis of the elderly with variable prognosis. Ann Med Interne (Paris). 2001;152:276-278.
9. Billstrom R, Johansson H, Johansson B, Mitelman F. Immune-mediated complications in patients with myelodysplastic syndromes-clinical and cytogenetic features. Eur J Haematol. 1995;55:42-48.
10. Bouali F, Berrah A, Si Ahmed-Bouali D, Harrieche F, Benhalima M, Hamladji RM, Arrada M. EImmunological abnormalities in myelodysplastic syndromes. Prospective study (series of 40 patients). Rev Med Interne. 2005;26:777-783.
11. Carvajal Mendez I, Garcia Vadillo JA, Herranz Varela A, Gonzalez Alvaro I, Casado Montero F, Castaneda Sanz S. EPolyarthritis associated with myelodysplastic syndromes. Rev Clin Esp. 1996;196:539-541.
12. Castro M, Conn DL, Su WP, Garton JP. Rheumatic manifestations in myelodysplastic syndromes. J Rheumatol. 1991;18:721-727.
13. Chandran G, Ahern MJ, Seshadri P, Coghlan D. Rheumatic manifestations of the myelodysplastic syndromes: a comparative study. Aust N Z J Med. 1996;26:683-688.
14. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108:419-425.
15. Cuende E, Guinea J, Ortiz de Urbina F, Torrabadella S, Templado JA, Vesga JC. Seronegative oligoarthritis in the course of refractory anaemia with excess blasts. Rheumatology (Oxford). 1999;38:373-375.
16. de Hollanda A, Beucher A, Henrion D, Ghali A, Lavigne C, Levesque H, Hamidou M, Subra JF, Ifrah N, Belizna C. Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study. Arthritis Care Res (Hoboken). 2011;63:1188-1194.
17. Enright H, Jacob HS, Vercellotti G, Howe R, Belzer M, Miller W. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol. 1995;91:403-408.
18. Fain O, Hamidou M, Cacoub P, Godeau B, Wechsler B, Paries J, Stirnemann J, Morin AS, Gatfosse M, Hanslik T, Belmatoug N, Bletry O, Cevallos R, Delevaux I, Fisher E, Hayem G, Kaplan G, Le Hello C, Mouthon L, Larroche C, Lemaire V, Piette AM, Piette JC, Ponge T, Puechal X, Rossert J, Sarrot-Reynauld F, Sicard D, Ziza JM, Kahn MF, Guillevin L. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57:1473-1480.
19. Fain O, Braun T, Stirnemann J, Fenaux P. Systemic and autoimmune manifestations in myelodysplastic syndromes. Rev Med Interne. 2011;32:552-559
20. George SW, Newman ED. Seronegative inflammatory arthritis in the myelodysplastic syndromes. Semin Arthritis Rheum. 1992;21: 345-354.
21. Giagounidis AA, Haase S, Germing U, Heinsch M, Aul C. Autoimmune disorders in two patients with myelodysplastic syndrome and 5q deletion. Acta Haematol. 2005;113:146-149.
22. Giannouli S, Voulgarelis M, Zintzaras E, Tzioufas AG, Moutsopoulos HM. Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study. Rheumatology. 2004;43:626-632.
23. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
24. Hamidou MA, Derenne S, Audrain MA, Berthelot JM, Boumalassa A, Grolleau JY. Prevalence of rheumatic manifestations and antineutrophil cytoplasmic antibodies in haematological malignancies. A prospective study. Rheumatology. 2000;39:417-420.
25. Hebbar M, Hebbar-Savean K, Fenaux P. ESystemic diseases in myelodysplastic syndromes. Rev Med Interne. 1995;16:897-904.
26. Hernandez-Beriain JA, Cuesta-Callardo I, Segura-Garcia C. Remitting seronegative symmetrical synovitis with pitting edema: a rheumatic manifestation of myelodysplastic syndrome? Rev Rhum Engl Ed. 1996;63:629-330.
27. Hubscher O, Vilches A, Solmesky S, Riveros D. Polymyalgia rheumatica in patients with myelodysplastic syndromes. J Rheumatol. 1996;23:792-793.
28. Kalra L, Delamere JP. Lymphoreticular malignancy and monoclonal gammopathy presenting as polymyalgia rheumatica. Br J Rheumatol. 1987;26:458-459.
29. Kaufman LD, Bahou WF, Fromowitz FB. Myelodysplasia presenting as monoarthritis. J Rheumatol. 1997;24:1446-1447.
30. Kohli M, Bennett RM. An association of polymyalgia rheumatica with myelodysplastic syndromes. J Rheumatol. 1994;21:1357-1359.
31. Kumar R, Garg ML, Jain GV, Maini PS. Sideroblastic anaemia presenting as monoarticular arthritis. Acta Haematol. 1974;52: 169-172.
32. Kuzmich PV, Ecker GA, Karsh J. Rheumatic manifestations in patients with myelodysplastic and myeloproliferative diseases. J Rheumatol. 1994;21:1649-1654.
33. Lee BN, Gao H, Cohen EN, Badoux X, Wierda WG, Estrov Z, Faderl SH, Keating MJ, Ferrajoli A, Reuben JM. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer. 2011;117:3999-4008.
34. Manganelli P, Delsante G, Bianchi G, Fietta P, Quaini F. Remitting seronegative symmetrical synovitis with pitting oedema in a patient with myelodysplastic syndrome and relapsing polychondritis. Clin Rheumatol. 2001;20:132-135.
35. Mimura J, Ishikawa T, Yabe H, Nagai K, Nakayama S. EArthritis in a case of myelodysplastic syndromes. Rinsho Ketsueki. 1988;29: 2292-2296.
36. Mok CC, Lau CS, Kumana CR. Polymyalgia rheumatica as the rheumatological manifestation of myelodysplastic syndrome in a Chinese patient. Br J Rheumatol. 1996;35:496-497.
37. Mufti GJ, Figes A, Hamblin TJ, Oscier DG, Copplestone JA. Immunological abnormalities in myelodysplastic syndromes. I. Serum immunoglobulins and autoantibodies. Br J Haematol. 1986;63: 143-147.
38. Nam EJ, Kang YM, Kang HR, Kim JH, Rho HJ, Lee MK, Hyun SH, Kim GW, Lee JM, Kim NS. Rheumatoid arthritis associated with myelodysplastic syndrome: a case report. J Korean Med Sci. 1999; 14:319-322.
39. Nozaki Y, Nagare Y, Kinoshita K, Urase F, Funauchi M. Successful treatment using tacrolimus plus corticosteroids in a patient with RA associated with MDS. Rheumatol Int. 2008;28:487-490.
40. Olive A, del Blanco J, Pons M, Vaquero M, Tena X. The clinical spectrum of remitting seronegative symmetrical synovitis with pitting edema. The Catalan Group for the Study of RS3PE. J Rheumatol. 1997;24:333-336.
41. Paira S, Graf C, Roverano S, Rossini J. Remitting seronegative symmetrical synovitis with pitting oedema: a study of 12 cases. Clin Rheumatol. 2002;21:146-149.
42. Pajus I, Amor B. ERheumatological manifestations associated with myelodysplastic and myeloproliferative syndromes. Rev Rhum Mal Osteoartic. 1992;59:11-16.
43. Pando JA, McLean RM, Flynn SD, Duffy TJ. Leukemic synovitis as the cause of arthritis in myelodysplastic syndrome. J Clin Rheumatol. 1995;1:125-127.
44. Pilorge S, Doleris LM, Dreyfus F, Park S. The autoimmune manifestations associated with myelodysplastic syndrome respond to 5-azacytidine: a report on three cases. Br J Haematol. 2011;153: 664-665.
45. Pipitone N, Masini L, Salvarini C. A case of arthritis and vasculitis associated with the refractory anemia with excess of blasts syndrome resistant to glucocorticoids treatment that responded favorably to TNF-alpha blockade. Clin Experimental Rheum. 2006;24:S31YS34.
46. Soubrier M, Dubost JJ, Fournier P, Guillemot C, Ristori JM. Myelodysplasia revealed by seropositive polyarthritis complicated by bicytopenia after the first methotrexate dose. Joint Bone Spine. 2002;69:239-240.
47. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937-951.